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1. Introduction 
Colorectal cancer (CRC) is the second most frequent malignant disease in Europe. Every year, 
412,000 people are diagnosed with this condition, and 207,000 patients die of it. Secondary 
prevention of CRC consists of early diagnosis of the disease in asymptomatic individuals 
(screening) and long term follow up of high risk patients (surveillance). Three groups of 
screening methods are currently available: stool testing (guaiac or immunochemical fecal 
occult blood tests – gFOBT and FIT respectively and DNA tests), endoscopic examinations 
(flexible sigmoidoscopy and colonoscopy) and radiologic examinations (computed 
tomographic colonography and double contrast barium enema). Colonoscopy is therefore 
used as the only screening method or as a second step in case of positive results of primary 
screening examination (two steps screening programs). From 27 countries in the European 
Union, the most frequently used test is FOBT (in 11 states). There is a choice between FOBT 
and colonoscopy in 6 countries. FOBT and flexible sigmoidoscopy is available in Italy. 
Currently, the only country using colonoscopy as the only screening method is Poland. At the 
end of 2010, the European guidelines for quality assurance in colorectal cancer screening and 
diagnosis were published, summarizing the evidence based medicine data for the efficacy, the 
interval, the age range, the risk-benefit and cost-effectiveness of colonoscopy screening. 
Unfortunately, prospective randomized trial on the effect of screening colonoscopy in the 
reduction of CRC incidence and mortality has not been published yet. Promising should be the 
NordICC study, which was introduced in 2009, however the results will be available in a 
fifteen year period. Series of recently published studies (Canada, Germany, Poland) focusing 
on the interval (post-colonoscopic) cancers confirmed the inadequate protection of proximal 
colon by colonoscopy. Another important issue would be the quality and safety of 
colonoscopy and the bowel cleansing. Concerning the surveillance colonoscopy, it plays a 
major role in specific follow up strategies in CRC high risk groups. It can be concluded that 
with some limitations, colonoscopy still remains the fundamental diagnostic and prophylactic 
examination in colorectal cancer screening and surveillance. 
2. Colorectal cancer epidemiology in Europe 
Colorectal cancer is the second most frequent malignant disease in developed countries. 
CRC incidence is generally higher in male population, and the risk of the disease increases 
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with age, as the majority of cases are diagnosed in patients over 50 years of age (Spann et 
al., 2002). Burden of European countries is ranked as the highest in the global statistics, 
both in incidence and mortality. Compared to the US, in 1998 – 2002 the European 
population showed a similar incidence for men, while that for women was slightly lower; 
the incidence in the USA for men and women was 38.6 and 28.3 respectively: in Europe it 
was 38.5 and 24.6 (ASR-W), as calculated per 100,000 inhabitants (Curado et al., 2007) . 
However, mortality over the same period of time was significantly higher  in Europe than 
in the US, both for men and women: in the USA the figures were 13.5 and 9.2 respectively, 
while in Europe they were 18.5 and 10.7 (ASR-W), as calculated per 100,000 inhabitants 
(World Health Organization [WHO], 2006). To document the situation in Europe, we used 
figures available from the international studies summarizing global and European 
epidemiologic data (Curado et al., 2007; Ferlay et al., 2004, 2007; Parkin et al., 2005). A 
detailed comparison of countries within Europe using the global age standardization 
(ASR-W) of incidence is presented in figure 1.  
 
 
Fig. 1. International comparison of CRC incidence in European countries 
Colorectal cancer comprises 12.9% of all newly-diagnosed carcinomas in the European 
population (men 12.8%, women 13.1%) and account for 12.2% of deaths caused by 
malignancy. Colorectal cancer is the second most common malignancy, after breast 
carcinoma (13.5% of all malignities), followed by bronchogenic carcinoma (12.1% of all 
malignancies). Every year 412,900 people are diagnosed with CRC in Europe, and 207,400 of 
them die of the disease (Ferlay et al., 2007). The average incidence has shown a tendency to 
rise in recent years, with an annual increment 0.5%. Data available regarding time trends of 
CRC mortality are displayed in figure 2. The CRC-related mortality has stabilized or shown 
a slight decrease over recent years.  
www.intechopen.com
 
Screening and Surveillance Colonoscopy 
 
3 
 
Fig. 2. Colorectal cancer mortality trends in Europe (men left, women right) 
3. Colorectal cancer prevention   
Colorectal cancer belongs to preventable cancers. Primary prevention focuses on dietary and 
lifestyle recommendations. Secondary prevention of CRC consists of early diagnosis of the 
disease in asymptomatic individuals (screening) in patients older than 50 years of age and a 
long term follow up of high risk patients (surveillance).  
4. Colorectal cancer screening 
Three groups of screening methods are currently available (see in the table below): stool 
testing (guaiac or immunochemical fecal occult blood tests – gFOBT and FIT respectively 
and DNA tests), endoscopic examinations (flexible sigmoidoscopy and colonoscopy) and 
radiologic examinations (computed tomographic colonography and double contrast barium 
enema). Colonoscopy is therefore used as the only screening method or as a second step in 
case of positive results of primary screening examination (Zavoral et al, 2009). 
 
Type of method Method 
Stool tests  
 
for presence of occult blood  
       guaiac-based (gFOBT) 
       immunochemical (FIT) 
for presence of abnormal DNA  
Endoscopic examinations 
 
Radiologic examinations 
 
flexible sigmoideoscopy (FS) 
colonoscopy  
computed tomographic colonography (CTC)  
double contrast barium enema (DCBE) 
Table 1. Overview of CRC screening methods 
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In 2008, the Report on the Implementation of the Council Recommendation on Cancer 
Screening, which provides the most comprehensive data available, was published (Karsa et 
al., 2008). According to this report, CRC screening is running or being established in 19 of 27 
EU countries. The target group contains approximately 136 million individuals suitable for 
CRC screening (aged 50 to 74 years). Of this number, 43% individuals come from 12 
countries where CRC population screening is performed or being prepared on either 
national or regional levels; 34% come from 5 countries where national population screening 
has been implemented (Finland, France, Italy, Poland, and United Kingdom). In 7 EU 
countries, national non-population based screening is carried out, which covers 27% of the 
target population. In 2007, gFOBT (which was the only test recommended by the Council of 
the European Union in 2003) was used as the only screening method in twelve countries 
(Bulgaria, Czech Republic, Finland, France, Hungary, Latvia, Portugal, Romania, Slovenia, 
Spain, Sweden, and United Kingdom). Colonoscopy was the only screening method used in 
Poland. In six countries, two types of tests were used: iFOBT and FS in Italy, and gFOBT and 
colonoscopy in Austria, Cyprus, Germany, Greece, and Slovak Republic. In the remaining 
eight states (Belgium, Denmark, Estonia, Ireland, Lithuania, Luxembourg, Malta, and the 
Netherlands), CRC screening has not been implemented yet. The age limit for the target 
population varies across the EU countries. In 2007, it was estimated that a total of 12 million 
individuals participated in CRC screening. 
4.1 Selected colonoscopy CRC screening programs  
Poland is currently the only state using colonoscopy as the only screening method, without 
the alternative of FOBT. An opportunistic screening programme was initiated in 2000, and 
by now, this had grown to 80 centers across the whole of Poland. The programme is 
financed by the Ministry of Health, independentantly from the overall healthcare system. 
The target population (asymptomatic individuals aged 55–66 years) is recruited through 
general practitioners. High emphasis is placed on the quality control of colonoscopies, with 
complications reported for 0.1% procedures, and no patient dying. The advantage of the 
programme consists in thorough monitoring and evaluation, including monitoring of 
interval cancers (Regula et al., 2006). 
Germany was the first country to introduce a population screening programme (in 1976) 
based on an annual gFOBT for individuals older than 44 years of age. Starting in 2002, the 
participants were offered a choice between colonoscopy at 55 years of age (in a ten-year 
interval) and FOBT in annual intervals between 50 and 54 years of age and in a two-year 
interval after 55 years of age. In case of FOBT positivity, screening colonoscopy followed. 
Between 2003 – 2008, there were 2 821 392 colonoscopies performed in over 2 100 practices 
all over Germany. The cumulative participation rate was 17.2% for women and 15.5% for 
men. Adenomas were diagnosed in a total of 19.4%, advanced adenomas in 6.4% and 
carcinomas in 0.9% of the examined patients. The majority of cancers were in early stage 
(UICC 47.3%, UICC II 22.3%, UICC III 20.7%, and UICC IV 9.6%). The overall and serious 
complication rate was 2.8 and 0.58 respectively per 1 000 colonoscopies. The cost analyses 
have proven the cost effectiveness of such screening (Pox et al., 2007). 
In the Czech Republic, CRC screening has many years of tradition. It was the second 
country in the world to start a nation-wide screening programme (in 2000), based on 
biennial gFOBT offered to asymptomatic individuals older than 50 years of age. In order to 
achieve higher compliance rate, screening colonoscopy was added to current FOBT 
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screening as an alternative method in 2009, in the same intervals as in the German 
programme. Both, gFOBT and various types of FIT are offered as well. During years 2006 – 
2010, there were 47 760 screening colonoscopies (FOBT+) and 5 574 primary screening 
colonoscopies performed. Adenomas and carcinomas were diagnosed in 16 454 (30.9%) and 
2 539 (4.8%) respectively. The proportion of advanced adenomas and generalized cancer 
(UICC stage III and IV) was 48% and 20.7% respectively (Zavoral et al., 2009). 
4.2 Screening colonoscopy studies 
The multinational NordICC (The Nordic-European Initiative on Colorectal Cancer) study 
was introduced in June 2009, however the results will be available in a fifteen year period. 
This study focuses on monitoring the effect of colonoscopy screening on reducing CRC 
incidence and mortality. The northern states of Europe (Norway, Sweden, and Iceland), 
Poland, and the Netherlands all participate. The Czech Republic, Hungary and Latvia are 
currently observers and may join the study later. According to the study protocol, a 
minimum of 66,000 individuals aged 55 to 64 years will be drawn directly from population 
registers in the participating countries and randomly assigned to either once-only 
colonoscopy screening or no screening (2:1 randomization, men and women). The primary 
objective is to compare the incidence and mortality against the control group after 15 years. 
At this time, more than 5 500 individuals have been examined so far and the recruitment 
will continue until the end of 2012 (NordiCC Study Protocol, 2011). 
CONFIRM (Colonoscopy vs. Fecal Immunochemical Test Reducing Mortality from 
Colorectal Cancer), the VA Cooperative study, is a multicenter, randomized, parallel group 
trial directly comparing screening colonoscopy with annual FIT screening in average risk 
individuals. The quantitative FIT (OC Sensor Diana) cut-off will be set at 100 ng/ml. The 
primary endpoint expected is CRC mortality reduction by 40% within a 10 year enrolment. 
The planned study duration is 12.5 years with 2.5 years of recruitment of 50 000 participants 
(1:1 randomization, 95% men, aged 50 – 75) and 2.5 years of follow-up for enrolled 
participants (Dominitz et al., 2011).  
COLONPREV (Colorectal Cancer Screening in Average-Risk Population: a Multicenter, 
Randomized Controlled Trial Comparing Immunochemical Fecal Occult Blood Testing 
versus Colonoscopy) study is being carried out since November 2008 in eight Spanish 
regions under the coordination of the public health system, primary care physicians and 
tertiary academic medical centers. Asymptomatic individuals aged 50 – 69 years have been 
randomized into two groups (1:1). Biennial quantitative FIT (OC Sensor, cut-off level 75 
ng/ml), followed by colonoscopy in case of its positivity has been offered to one group and 
colonoscopy to the second group. First preliminary results are expected in June 2011 
(Castellas et al., 2011) 
The Japan Polyp Study (JPS) is a multicenter randomized control trial focusing on 
postpolypectomy surveillance and conducted in eleven centers since February 2003. Two 
complete colonoscopies with the removal of all neoplastic lesions (to reach “clean colon”) 
have been performed to the enrolled patients who have been randomized into two groups 
(1:1) afterwards, according to the colonoscopy follow-up interval. One group underwent a 
colonoscopy after 48 months, the second group at 24 and 48 months. From a total of 4 752 
individuals, 3 926 (83%) agreed with the initial colonoscopy and 2 757 (58%) patients were 
randomized. There has been a great impact on polyp distribution and macroscopic type in 
the first two initial colonoscopies. Very high adenoma detection (63%) was reached 
(Matsuda, 2011). 
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4.3 Screening colonoscopy characteristics 
At the end of 2010, the European guidelines for quality assurance in colorectal cancer 
screening and diagnosis were published, summarizing the evidence based medicine data for 
the efficacy, the interval, the age range, the risk-benefit and cost-effectiveness of colorectal 
cancer screening, including sigmoidoscopy (FS) and colonoscopy screening analysis.   
4.3.1 Evidence for effectiveness of sigmoidoscopy screening 
Flexible sigmoidoscopy screening reduces colorectal cancer (CRC) incidence and mortality if 
performed in an organised screening programme with careful monitoring of the quality and 
systematic evaluation of the outcomes, adverse effects and costs (Atkin et al., 2010). The 
evidence on the efficacy is avaible from randomised controlled trials (RCTs). The most 
important one is the large UK study in which 57 237 individuals were randomised into the 
screening group for a once-only sigmoidoscopy alone. This study found a significant 31% 
reduction in CRC mortality and also a significant reduction in CRC incidence from 
sigmoidoscopy in an intention-to-treat analysis (Atkin et al., 2010).  
The optimal interval for sigmoidoscopy screening was only assessed in two indirect studies 
that only considered intervals of three and five years (Platell et al., 2002, Schoen et al., 2003). 
The UK flexible sigmoidoscopy screening study showed that there was little attenuation of 
the protective effect of sigmoidoscopy after 11 years of follow-up. This is in line with the 
evidence for colonoscopy screening. In conclusion, the optimal interval for endoscopy 
screening should not be less than 10 years and may even be extended to 20 years (Atkin et 
al., 2010). 
There is limited evidence suggesting that the best age range for flexible sigmoidoscopy 
screening should be between 55 and 64 years (Segnan et al., 2007). One study 
demonstrated that elderly subjects (75 years old) have an increased rate of endoscopist-
reported difficulties and a higher rate of incomplete examinations compared to subjects 
aged 50–74 years (Pabby et al, 2005). Average-risk sigmoidoscopy screening should be 
discontinued after 74 years of age, given the increasing co-morbidity in this age range 
(Atkin et al., 2010). 
4.3.2 Evidence for effectiveness of colonoscopy screening 
Limited evidence exists on the efficacy of colonoscopy screening on CRC incidence and 
mortality (Atkin et al, 2010). However, two recent case–control studies found a significant 
reduction of 31% in CRC mortality (Baxter et al., 2009) and 48% in advanced neoplasia 
detection rates (Brenner et al., 2010). The reduction in these studies was limited to the 
rectum and left side of the colon. No significant reduction was found in right-sided disease. 
Cross-sectional surveys have shown that colonoscopy is more sensitive than sigmoidoscopy 
in detecting adenomas and cancers and that this increased sensitivity could translate into 
increased effectiveness (Walsh et al., 2003). The efficacy of colonoscopy as a primary 
screening test has not been proven by prospective randomized control trial.  
The optimal interval for colonoscopy screening has been assessed in a cohort study and a 
case-control study. The cohort study found that CRC incidence in a population with 
negative colonoscopy was 31% lower than general population rates and remained reduced 
beyond 10 years after the negative colonoscopy (Singh et al., 2006). Similar results were 
obtained in the case–control study (Brenner et al., 2006) where the reduction of risk of CRC 
was 74 % and persisted up to 20 years.  
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Screening colonoscopies do not need to be performed at intervals shorter than 10 years and  
this time interval may even be extended to 20 years (Atkin et al., 2010).  
There is no direct evidence confirming the optimal age range for colonoscopy screening. 
Indirect evidence suggests that the prevalence of neoplastic lesions in the younger 
population (less than 50 years) is too low to justify colonoscopic screening, while in the 
elderly population (more than 75 years) the lack of benefit could be a major issue (Pabby et 
al., 2005). The optimal age for a single colonoscopy appears to be around 55 years. Average 
risk colonoscopy screening should not be performed before age 50 and should be 
discontinued after 74 years of age (Atkin et al., 2010). 
5. Colonoscopic surveillance following adenoma removal 
The adenomatous polyp is the precursor of most colorectal cancers and is the most 
frequently detected lesion during a colonoscopy examination (Lieberman et al., 2000). 
Hyperplastic polyps, on the other hand, usually have no clinical significance. Based on the 
statistics, in 33 % – 50 % of patients consecutive adenomas develop within three years after 
the removal of first adenoma. In addition, in 0,3-0,9 % of cases colorectal carcinoma is 
detected within five years (Alberts et al., 2000; Arber et al., 2006; Baron et al., 2006; Martinez 
et al., 2009; Robertson et al., 2005). Most of these adenomas and malignancies are, however, 
represented by lesions missed during the first colonoscopy. The quality of a colonoscopic 
examination must therefore be emphasized. Medical centers involved in screening 
programmes thus often undergo quality controls. One of the key aims of a surveillance 
colonoscopy is to detect all new lesions or lesions that have been missed at baseline 
colonoscopy before they progress to malignancy. The other aim of a follow-up colonoscopy 
is the detection of colorectal carcinoma at an early, prognostically more favorable stage 
(Robertson et al., 2005).  
 
 
Picture 1. Sessile polyp - white light 
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Picture 2. Sessile polyp - NBI (narrow band imaging) 
 
 
 
Picture 3. Sessile polyp - Patent Blue injection   
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Picture 4. Postpolypectomy site 
Colonoscopy is an invasive method with a small, however not insignificant risk of possible 
complications, amongst which are perforation (0,06 % diagnostic and 2 % therapeutical 
colonoscopies) and hemorrhage after polypectomy (02,-2,7 % according to size of lesion) 
(Rosen et al., 1993). Surveillance colonoscopies represent a burden for endoscopic centers 
prolonging the waiting lists. For these reasons, surveillance colonoscopies should be carried 
out in recommended intervals in order to prevent the development of colorectal carcinoma. 
The malignant potential of an adenoma depends on its size, histological verification and the 
grade of dysplasia. It is higher in advanced adenomas (larger than 10 mm or more, with a 
villous component or a high grade dysplasia). Recent studies show, that the villous 
component is a less significant predictor for the development of malignancy than the 
remaining two factors.   
5.1 Risk factors for advanced adenomas and colorectal cancer after baseline 
polypectomy 
The risk of detection of advanced adenoma or carcinoma during a surveillance colonoscopy 
depends on the quality of the first (baseline) colonoscopy and the characteristics of the 
removed polyp.   
It is generally agreed that high quality colonoscopies carried out less frequently are more 
efficient in the prevention of colorectal cancer than more frequent colonoscopies of a lower 
quality. Colonoscopy examination should only be carried out after adequate bowel 
preparation in order to properly visualize bowel mucosa. Patients with poor bowel 
preparation have to be invited for a repeated colonoscopy, considering the colonoscopy was 
well indicated in the first place. The examination must also be complete (reaching the 
caecum) and the withdrawal of an endoscope should be slow and careful. All detected 
lesions have to be removed carefully, ideally as hoc during their detection since they can 
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easily be overlooked during the next examination. Polyp removal must be done during the 
withdrawal of a scope due to the possible risk of bleeding and perforation.  
Based on the following meta-analysis (Saini et al., 2006) it is obvious that a personal history 
of 3 adenomatous polyps increases the risk for the presence of advanced adenoma 2x, 
whereas the history of five polyps increases the risk at a surveillance colonoscopy 4x, as 
opposed to the detection of a single polyp during a baseline colonoscopy. The polyp size 
also plays a significant role. The real size is considered to be the size of the histological 
specimen measured by a pathologist. In case a piece-meal polypectomy is performed, the 
size is based upon the judgment of the endoscopist (comparing the lesion with a known size 
of biopsy forceps). Adenomas measuring between 10 to 20 mm have twice the increased 
risk, adenomas measuring 20 mm or more have 3x the increased risk of turning to 
malignancy as opposed to small adenomas (up to 10mm) (Cafferty et al., 2007).   
Adenoma histology does not play as significant role as believed earlier. However, a villous 
structure polyp increases the chance of villous adenoma detection during a surveillance 
colonoscopy (Cafferty et al., 2007). On the other hand, the presence of high grade dysplasia 
significantly increases the risk of malignant changes in adenomas of varying size (Saini et 
al., 2006). 
Based on the studies listed below, the localization of polyp in the right colon increases the 
risk of advanced colorectal neoplasia 1,5-2,5 times as opposed to its localization in the left 
colon (Laiyemo et al., 2009; Martinez et al., 2009; Saini et al., 2006)  
5.2 Risk factors in patients    
One of the risk factors is older age, which correlates with the higher  incidence of 
advanced colorectal neoplasia, at the same time it is related to an increased difficulty of a 
colonoscopy examination and its performance, worse bowel preparation and a higher risk 
of complications related to the examination itself. It is always necessary to proceed 
individually recognizing all comorbidities of a patient, the benefit of the examination 
itself, whilst considering whether the lead time for progression of adenoma to colorectal 
cancer does not exceed the life-expectancy of an individual, particularly in patients aged 
75 years or older. The upper age boundary for surveillance cessation is usually 75 years of 
age. A positive family history for an adenoma, unless a dominant genetic disease is 
suspected, does not require any special precautions during surveillance colonoscopies 
(Atkin et al., 2010).   
5.3 Stratification of risk factors in patients  
According to European guidelines for the quality assurance in colorectal cancer screening 
and diagnosis (2010), the degree of risk should be determined based on the findings at 
baseline colonoscopy. It is recommended to divide patients into groups with low, 
intermediate and high risk of colorectal neoplasia development, thus more easily 
determining the interval of colonoscopy examinations. Based on these results, further 
surveillance can be modified (Atkin et al., 2010).  
Low risk group: Patients with one or two polyps measuring up to 10 mm, with tubular 
structure and low grade dysplasia are considered to be in low risk of developing colorectal 
carcinoma and may further continue in the population screening programme. However, it is 
necessary to also consider their age, family history, degree of bowel preparation and the 
quality of colonoscopy examinations. 
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Intermediate risk group: Patients with three or four small polyps, or one adenomatous 
polyp measuring ≥ 10 mm and  20 mm, or a polyp with villous structure or high grade 
dysplasia, are considered to be in an intermediate risk group and should have a follow up 
colonoscopy in a three year interval. If there is a negative finding during the first 
surveillance colonoscopy another examination is indicated 5 years after the previous one. 
After two surveillance colonoscopies with a physiological finding, the patient can transfer to 
the common population colorectal cancer screening programme. If low or intermediate risk 
adenomas are detected, the patient should further be placed in an intermediate risk group 
(next surveillance colonoscopy being in a 3 year interval), in high risk polyps the next 
colonoscopy is recommended within 1 year. 
High risk group: Patients with five small polyps or one polyp measuring at least 20mm or 
more are indicated to have a surveillance colonoscopy within one year from their baseline 
colonoscopy. If there is a negative finding or an adenoma with intermediate risk is detected, 
the next examination is recommended after three years. Two negative controls shift the 
interval for another colonoscopy by further 5 years. When a high risk adenoma is detected 
during a surveillance colonoscopy, an early examination is necessary – within 1 year. The 
aim of an early surveillance examination is to detect concurrent lesions that were not picked 
up during a baseline colonoscopy. 
5.4 Recommendations for surveillance in chosen colonoscopy findings 
Endoscopically removed pT1 carcinoma is considered a high risk lesion based on its 
biological characteristics, the first surveillance colonoscopy interval thus being within 12 
months from the first one (Chu et al., 2003; Di Gregorio et al., 2005; Rex et al., 2006).   
For surveillance purposes, serrated adenomas (i.e., traditional serrated adenomas and mixed 
polyps with at least one adenomatous component) should be dealt with using standard 
recommendations like any other adenoma. Currently, there is no data available that would 
explicitly certify the need for any other surveillance programme.  
There has been no proof that a small hyperplastic polyp has an increased risk of colorectal 
carcinoma, patients with this finding are therefore placed in standard population screening 
programme. Individuals with one or more hyperplastic polyps measuring more than 10mm, 
or with non-neoplastic serrated lesions of the colon, or with multiple small lesions in the 
right colon, are considered to have a higher risk of developing colorectal neoplasia. 
However, accurate recommendations cannot be reliably determined for the current lack of 
data (Atkin et al., 2010).   
Large sessile lesion removed by a piece-meal resection should be checked within 2-3 
months, so that small areas of residual tissue can be treated endoscopically early enough. 
Within the next 3 months they can easily be identified using India ink tattooing and ideally 
completely eradicated. When a large residual finding is detected during a follow up 
examination, further endoscopic or surgical treatment should be considered.   
5.5 Stopping surveillance 
Stopping surveillance depends on several factors, not only on the characteristics of detected 
polyps, but also on age, comorbidities and personal wishes. The upper age boundary for 
surveillance colonoscopy is considered to be 75 years or older (Atkin et al., 2010). At this 
stage, patients can discontinue the surveillance programme and return to the population 
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screening programme. On the other hand, patients undergoing the surveillance programme 
being followed up endoscopically are not indicated to continue with the FOBT.  
6. Conclusion  
Colonoscopy plays a major role in colorectal cancer screening. Recently published 
Europeans guidelines showed that although no randomized control study on the efficacy of 
colonoscopy has been completed yet, the recent case-control studies found a significant 
reduction of 31% CRC mortality. Very promising is the NordICC trial which could confirm 
these results. To reduce the appearance of interval cancer, colonoscopy quality control and 
adequate bowel preparation is necessary. Colonoscopy can be considered an effective and 
safe procedure.  
A well organized surveillance programme for patients with adenoma, advanced adenoma 
or carcinoma is just as important as a baseline colonoscopy examination with its quality and 
precision being the determining factors of the follow up intervals. Patients should be 
divided into three categories using simple criteria, depending on the presumed risk of 
developing colorectal cancer, while being endoscopically followed up at given intervals. It is 
always necessary to take into consideration age, comorbidities, personal and family history, 
and the personal wish of each individual. 
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